TissGeneSummary for SLC2A9 |
Gene summary |
Basic gene information | Gene symbol | SLC2A9 |
Gene name | solute carrier family 2 (facilitated glucose transporter), member 9 | |
Synonyms | GLUT9|GLUTX|UAQTL2|URATv1 | |
Cytomap | UCSC genome browser: 4p16.1 | |
Type of gene | protein-coding | |
RefGenes | NM_001001290.1, NM_020041.2, | |
Description | GLUT-9glucose transporter type 9human glucose transporter-like protein-9solute carrier family 2, facilitated glucose transporter member 9urate voltage-driven efflux transporter 1 | |
Modification date | 20141211 | |
dbXrefs | MIM : 606142 | |
HGNC : HGNC | ||
Ensembl : ENSG00000109667 | ||
HPRD : 05848 | ||
Vega : OTTHUMG00000044263 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_SLC2A9 | |
BioGPS: 56606 | ||
Pathway | NCI Pathway Interaction Database: SLC2A9 | |
KEGG: SLC2A9 | ||
REACTOME: SLC2A9 | ||
Pathway Commons: SLC2A9 | ||
Context | iHOP: SLC2A9 | |
ligand binding site mutation search in PubMed: SLC2A9 | ||
UCL Cancer Institute: SLC2A9 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | TiGER,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Kidney | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | KIRC,KIRP,KICH | |
Reference showing the relevant tissue of SLC2A9 | ||
Description by TissGene annotations | Protective TissGene in OS |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID |
Top |
TissGeneExp for SLC2A9 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
LIHC | 0.267836296 | 2.161030296 | -1.893194 | 1.13E-07 | 7.87E-07 |
KICH | -1.352765704 | 1.080062296 | -2.432828 | 9.36E-10 | 5.93E-09 |
PRAD | -1.642452627 | 0.176501219 | -1.818953846 | 4.12E-11 | 1.05E-09 |
Top |
TissGene-miRNA for SLC2A9 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for SLC2A9 |
TissGeneSNV for SLC2A9 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.N61S | LGG | 1 |
p.S432F | PRAD | 1 |
p.R169H | COAD | 1 |
p.P165L | SKCM | 1 |
p.Q188L | LUAD | 1 |
p.R169H | PRAD | 1 |
p.G170* | UCEC | 1 |
p.G45C | UCEC | 1 |
p.I116M | LUAD | 1 |
p.R198H | PRAD | 1 |
p.I56M | BLCA | 1 |
p.Q316E | BRCA | 1 |
p.A118T | PAAD | 1 |
p.L364F | SKCM | 1 |
p.S9P | READ | 1 |
p.Q473H | LUAD | 1 |
p.P434Q | LUAD | 1 |
p.Q217L | LUAD | 1 |
p.G491V | LUSC | 1 |
p.D225G | LUAD | 1 |
p.R49S | COAD | 1 |
p.F69S | KIRP | 1 |
p.M126I | LUAD | 1 |
p.E237K | SKCM | 1 |
p.L135I | HNSC | 1 |
p.S264N | SKCM | 1 |
p.M145I | SKCM | 1 |
p.S254F | BLCA | 1 |
p.R8Q | HNSC | 1 |
p.G432D | LUSC | 1 |
p.K535E | LIHC | 1 |
p.V457I | STAD | 1 |
p.F172L | CESC | 1 |
p.R8Q | BLCA | 1 |
p.P405Q | LUAD | 1 |
p.S486F | SKCM | 1 |
p.L354F | SKCM | 1 |
p.G278S | ESCA | 1 |
p.Q444* | SKCM | 1 |
p.T401K | ESCA | 1 |
p.P500H | UCEC | 1 |
p.S82F | SKCM | 1 |
p.E194K | THCA | 1 |
p.E10* | LUAD | 1 |
p.X512Y | SKCM | 1 |
p.E191D | OV | 1 |
p.T113A | PAAD | 1 |
p.G25R | COAD | 1 |
p.R285C | SKCM | 1 |
p.G117R | SKCM | 1 |
p.Q245R | LUAD | 1 |
p.L106I | HNSC | 1 |
p.G9R | LGG | 1 |
p.R257H | STAD | 1 |
p.V105I | SKCM | 1 |
p.A491E | SARC | 1 |
p.T368N | SARC | 1 |
p.I87M | LUAD | 1 |
p.P321S | SKCM | 1 |
p.G362S | STAD | 1 |
p.Q415R | COAD | 1 |
p.G46R | SKCM | 1 |
p.S359R | STAD | 1 |
p.V151I | COAD | 1 |
p.S330R | STAD | 1 |
p.A463V | READ | 1 |
p.G249S | ESCA | 1 |
p.L220H | SKCM | 1 |
p.L385M | COAD | 1 |
p.G361E | UCEC | 1 |
p.A513T | BRCA | 1 |
p.S482N | SKCM | 1 |
p.P380L | SARC | 1 |
p.R476K | SKCM | 1 |
p.A161V | UCEC | 1 |
p.M158V | LUAD | 1 |
p.T502N | KIRC | 1 |
p.T84A | PAAD | 1 |
p.R142C | LGG | 1 |
p.Q274R | LUAD | 1 |
p.F469S | UCEC | 1 |
p.A89T | PAAD | 1 |
p.Y188* | LUAD | 1 |
p.R171C | STAD | 1 |
p.I180M | LUAD | 1 |
p.D281N | PAAD | 1 |
p.T374I | SKCM | 1 |
p.A454T | UCEC | 1 |
p.Y159* | LUAD | 1 |
p.V151I | PRAD | 1 |
Top |
TissGeneCNV for SLC2A9 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for SLC2A9 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
TCGAfusionPortal | PRADA | BLCA | TCGA-DK-A3X1-01A | SLC2A9-RAD51 | In-frame | Chr4:10020599 | Chr15:40998375 |
TCGAfusionPortal | PRADA | BRCA | TCGA-A8-A09M-01A | SLC30A9-SLC2A9 | Out-of-frame | Chr4:42003797 | Chr4:9909969 |
Top |
TissGeneNet for SLC2A9 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for SLC2A9 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for SLC2A9 |
TissGeneDrug for SLC2A9 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for SLC2A9 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |
umls:C0473219 | Renal hypouricemia | 16 | BeFree,CTD_human |
umls:C0018099 | Gout | 12 | CTD_human,GAD,GWASCAT |
umls:C0740394 | Hyperuricemia | 10 | BeFree,CTD_human,GAD |
umls:C0022660 | Kidney Failure, Acute | 5 | BeFree |
umls:C2677549 | Hypouricemia, Renal, 2 | 3 | CLINVAR,CTD_human,UNIPROT |
umls:C3160858 | Posterior reversible encephalopathy syndrome | 3 | BeFree |
umls:C0007222 | Cardiovascular Diseases | 2 | BeFree |
umls:C0010054 | Coronary Arteriosclerosis | 2 | BeFree |
umls:C0010068 | Coronary heart disease | 2 | BeFree |
umls:C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 2 | BeFree,GAD |
umls:C0524620 | Metabolic Syndrome X | 2 | BeFree,GAD |
umls:C0744466 | gout tophaceous | 2 | BeFree |
umls:C1561643 | Chronic Kidney Diseases | 2 | BeFree |
umls:C0002395 | Alzheimer's Disease | 1 | GAD |
umls:C0003469 | Anxiety Disorders | 1 | BeFree |
umls:C0003850 | Arteriosclerosis | 1 | BeFree |
umls:C0003868 | Arthritis, Gouty | 1 | BeFree |
umls:C0004153 | Atherosclerosis | 1 | BeFree |
umls:C0008925 | Cleft Palate | 1 | BeFree |
umls:C0009451 | Communicating Hydrocephalus | 1 | BeFree |
umls:C0020538 | Hypertensive disease | 1 | BeFree |
umls:C0026764 | Multiple Myeloma | 1 | BeFree |
umls:C0027051 | Myocardial Infarction | 1 | BeFree,GAD,LHGDN |
umls:C0028754 | Obesity | 1 | GAD |
umls:C0031572 | Phobia, Social | 1 | BeFree |
umls:C0040336 | Tobacco Use Disorder | 1 | GAD |
umls:C0221248 | Tophus | 1 | BeFree |
umls:C0392525 | Nephrolithiasis | 1 | BeFree,GAD |
umls:C0700634 | Serum uric acid observed | 1 | GAD |
umls:C0852949 | Arteriopathic disease | 1 | BeFree |
umls:C1956346 | Coronary Artery Disease | 1 | BeFree,GAD,LHGDN |